ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COAG vs VIR // PIOTROSKI F-SCORE QUALITY

Hemab Therapeutics Holdings Inc. (NASDAQ) VS. Vir Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: COAG 1 — VIR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COAG VS. VIR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COAG VIR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -19.74% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -7.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.40 — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE — 4/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 67.2 53.8 +13.35 COAG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.89B $2.01B -$120.9M VIR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COAG REV VIR REV COAG GROSS % VIR GROSS % COAG FCF VIR FCF
FY 2025 $0 $68.6M — 98.0% — -$396.6M
FY 2024 — $74.2M — 98.0% — -$453.7M
FY 2023 — $86.2M — — — -$778.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COAG // BETA —
VIR // BETA —